KRAS Mutant Specific Tools And Services

Biotechno Labs along with its renowned principal BPS Biosciences has introduced products related to KRAS protein for the expedition of cancer research. KRAS is an important protein in the RAS/MAPK signaling pathway. KRAS has emerged as a target of significant clinical interest. It has been found that mutations in the KRAS protein promote the pathogenesis of 20-30% of human cancers. Testing a patient for types of KRAS mutants serves as a highly predictive marker for success rates to various types of lung and colon cancer therapies. Specifically, the KRAS G12C mutant is a key drug target due to its proximity to a shallow binding site.

The development of covalent inhibitors against KRAS (G12C) are currently in clinical testing. The company has developed nucleotide exchange assay kits for KRAS mutants G12D and G12C. Their kits are well-suited for identifying specific inhibitors by enabling sensitive measurements of GDP to GTP exchange mediated by KRAS mutants. These 384-well format kits provide a convenient solution for compound library screening. To further accelerate the KRAS research they have generated a library of purified KRAS mutant proteins, in both isoforms A and B, with or without pre-loaded GTP.